SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arena Pharmaceuticals (ARNA)
ARNA 99.990.0%Mar 15 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (119)2/21/2006 7:27:36 PM
From: Biotech Jim  Read Replies (1) of 2274
 
Could be related to potential risk for development or exacerbation of MS. delta9THC shows efficacy in the experimental autoimmune encephalomyelitis model, which is reasonable but not perfect model for MS. In one of the RIO studies, there was the development of MS in an equal # of PBO vs rimonabant treated patients.

Regarding smoking cessation, rimonabant in man shows what I would consider modest at best efficacy. On the other hand varenicline, a PFE product candidate, shows fairly dramatic efficacy for smoking cessation and is under priority review at the agency for smoking cessation. Varenicline is a subtype selective nicotinic receptor partial agonist.

BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News